SC
BMRN icon

Steven Cohen’s BioMarin Pharmaceuticals BMRN Stock Holding History

Steven Cohen’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100,000
Closed -$5.65M – 4038
2026
Q1 		$5.65M Buy
+100,000
New +$5.83M 0.01% 1623
2025
Q1 		– Sell
-300,000
Closed -$19.7M – 2059
2024
Q4 		$19.7M Hold
300,000
– – 0.04% 460
2024
Q3 		$21.1M Buy
+300,000
New +$25.1M 0.05% 402
2022
Q2 		– Sell
-84,900
Closed -$6.55M – 1409
2022
Q1 		$6.55M Buy
+84,900
New +$7.1M 0.03% 625
2018
Q1 		– Sell
-883,400
Closed -$78.8M – 948
2017
Q4 		$78.8M Buy
883,400
+564,400
+177% +$49.1M 0.34% 71
2017
Q3 		$29.7M Buy
+319,000
New +$28.2M 0.13% 190

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Steven Cohen's BMRN Position: Q2 2026 in Review

Steven Cohen sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 1,199,206 shares — an estimated $67.7M sold.

Steven Cohen first reported a position in BMRN in Q2 2014 and held it in 30 quarters. The position peaked at $118M in Q1 2024. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Steven Cohen reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 1,199,206 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $67.7M.
  • Steven Cohen first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 30 quarters.
  • Steven Cohen's BioMarin Pharmaceuticals position peaked at $118M in Q1 2024.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.